Advertisement

Topics

Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit

17:35 EDT 29 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Extended RAS Panel helps identify colorectal cancer patients eligible for Amgen’s Vectibix Illumina, Inc. (NASDAQ:ILMN) today announced its Extended RAS Panel, an FDA-approved next-generation sequencing (NGS) kit th...

Other Sources for this Article

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
IR@illumina.com
or
Media:
Jen Carroll, 858-882-6822
PR@illumina.com

NEXT ARTICLE

More From BioPortfolio on "Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...